Imagine a stock that pays you 100% income on your money every year… and continues to do so for the rest of your life. $1,000 in savings would pay you $1,000. $10,000 would pay you an extra $10,000. $100,000 would pay you $100,000. And again, that’s every year. We never thought an investment like that would be possible… Until we saw this.
Week of April 22, 2019
Happy Easter and Passover.
U.S. indices closed higher last week. The Dow Jones jumped another 110 points to 26,559, nearing its all-time high of 26,951.
Two new IPOs hit the market last week, with Pinterest (PINS) and Zoom (ZM) making their debut. PINS traded 28.4% higher. ZM traded 72.2% higher.
Unemployment claims came in at their lowest rate in more than 49 years. Initial claims dropped to 192,000 for the week ending April 13, 2019. That’s the lowest since September 1969.
Some of the top earnings reports to watch for the week of April 22, 2019 include Hasbro Inc., The Coca-Cola Company, Procter & Gamble, Lockheed Martin Company, Twitter, Verizon Communications, and Facebook.
Here are some of the top stocks to watch.
Opportunity No. 1
Huya, Inc. (HUYA)
HUYA is likely to push higher over the long-term as a market leader with a game live streaming platform. This market has already grown 40% in recent years, and is expected to grow another 20% annually. It’s another way to trade the growing and quite explosive eSports boom. Technically, it appears the stock has found strong support at $22.32 after pulling back from $30.
Opportunity No. 2
Aurora Cannabis (ACB)
Top cannabis stocks like ACB are a long-term buy and hold, especially as U.S. approval ratings just begin to tick higher. According to The General Social Survey conducted by NORC at the University of Chicago, 61% of those surveyed support legalization. A Gallup survey found that 66% of Americans are in favor of legalization. That’s up from just 60% in 2016.
Opportunity No. 3
TG Therapeutics (TGTX)
Biotech is always an exciting trade. And from what we can see from TGTX study data, this stock could be just as exciting. In a mid-stage trial for refractory marginal zone lymphoma (MZL), the drug easily met its primary endpoint of overall response rate. The FDA also just granted umbralisib a Breakthrough Therapy Designation for the treatment. Even better, it’s showing a favorable efficacy when compared to other drugs, including an AbbVie drug.